Myeloperoxidase, released from activated neutrophils, modulates vascular inflammation and NO bioavailability [65], linking it to HF post-ischemic injury [66], atrial structural remodeling, and atrial fibrillation (AF) risk [67]. The gene discussed is MPO; the disease is atrial fibrillation.